Reactive Oxygen-Related Diseases: Therapeutic Targets and Emerging Clinical Indications

Antioxidants and Redox Signaling

Volumn 23, Issue 14, 2015, Pages 1171-1185

  Casas, Ana I ^a   Dao, V Thao Vi ^a   Daiber, Andreas ^b   Maghzal, Ghassan J ^c   Di Lisa, Fabio ^d,e   Kaludercic, Nina ^e   Leach, Sonia ^f   Cuadrado, Antonio ^g   Jaquet, Vincent ^h   Seredenina, Tamara ^h   Krause, Karl H ^h   López, Manuela G ⁱ   Stocker, Roland ^c   Ghezzi, Pietro ^f   Schmidt, Harald H H W ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF PADOVA   (Italy)

^e CNR   (Italy)

^f BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

^g INSTITUTO DE SALUD CARLOS III   (Spain)

^h UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

ⁱ INSTITUTO TEÓFILO HERNANDO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); ANTIOXIDANT; ENDOTHELIAL NITRIC OXIDE SYNTHASE; MYELOPEROXIDASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; XANTHINE OXIDASE; PEROXIDASE;

ARTICLE; GENERAL ASPECTS OF DISEASE; HUMAN; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; ANIMAL; METABOLISM; PHYSIOLOGY;

ANIMALS; ANTIOXIDANTS; HUMANS; MONOAMINE OXIDASE; NADPH OXIDASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXIDATIVE STRESS; PEROXIDASE; REACTIVE OXYGEN SPECIES; XANTHINE OXIDASE;

EID: 84947732762     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2015.6433     Document Type: Article

References (157)

1. Adolfsson R, Gottfries CG, Oreland L, Wiberg A, and Winblad B. Increased activity of brain and platelet monoamine oxidase in dementia of Alzheimer type. Life Sci 27: 1029-1034, 1980.
2. Alderton WK, Cooper CE, and Knowles RG. Nitric oxide synthases: structure, function and inhibition. Biochem J 357: 593-615, 2001.
3. Alexander JH, Reynolds HR, Stebbins AL, Dzavik V, Harrington RA, Van de Werf F, and Hochman JS. Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA 297: 1657-1666, 2007.
4. Altenhofer S, Kleikers PW, Radermacher KA, Scheurer P, Rob Hermans JJ, Schiffers P, Ho H, Wingler K, and Schmidt HH. The NOX toolbox: validating the role of NADPH oxidases in physiology and disease. Cell Mol Life Sci 69: 2327-2343, 2012.
5. Altenhofer S, Radermacher KA, Kleikers PW, Wingler K, and Schmidt HH. Evolution of NADPH oxidase inhibitors: selectivity and mechanisms for target engagement. Antioxid Redox Signal 23: 406-427, 2015.
6. Anderson EJ, Efird JT, Davies SW, O'Neal WT, Darden TM, Thayne KA, Katunga LA, Kindell LC, Ferguson TB, Anderson CA, Chitwood WR, Koutlas TC, Williams JM, Rodriguez E, and Kypson AP. Monoamine oxidase is a major determinant of redox balance in human atrial myocardium and is associated with postoperative atrial fibrillation. J Am Heart Assoc 3: e000713, 2014.
7. Antoniades C, Shirodaria C, Warrick N, Cai S, de Bono J, Lee J, Leeson P, Neubauer S, Ratnatunga C, Pillai R, Refsum H, and Channon KM. 5-methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling. Circulation 114: 1193-1201, 2006.
8. Atochin DN and Huang PL. Endothelial nitric oxide synthase transgenic models of endothelial dysfunction. Pflugers Arch 460: 965-974, 2010.
9. Babelova A, Avaniadi D, Jung O, Fork C, Beckmann J, Kosowski J, Weissmann N, Anilkumar N, Shah AM, Schaefer L, Schroder K, and Brandes RP. Role of Nox4 in murine models of kidney disease. Free Radic Biol Med 53: 842-853, 2012.
10. Baldus S, Eiserich JP, Mani A, Castro L, Figueroa M, Chumley P, Ma W, Tousson A, White CR, Bullard DC, Brennan M-L, Lusis AJ, Moore KP, and Freeman BA. Endothelial transcytosis of myeloperoxidase confers specificity to vascular ECM proteins as targets of tyrosine nitration. J Clin Invest 108: 1759-1770, 2001.
11. Banfi B, Molnar G, Maturana A, Steger K, Hegedus B, Demaurex N, and Krause KH. A Ca(2+)-activated NADPH oxidase in testis, spleen, and lymph nodes. J Biol Chem 276: 37594-37601, 2001.
12. Bedard K, Jaquet V, and Krause KH. NOX5: from basic biology to signaling and disease. Free Radic Biol Med 52: 725-734, 2012.
13. Bedard K and Krause KH. The NOX family of ROSgenerating NADPH oxidases: physiology and pathophysiology. Physiol Rev 87: 245-313, 2007.
14. Bialecka M, Klodowska-Duda G, Honczarenko K, Gawronska-Szklarz B, Opala G, Safranow K, and Drozdzik M. Polymorphisms of catechol-0-methyltransferase (COMT), monoamine oxidase B (MAOB), Nacetyltransferase 2 (NAT2) and cytochrome P450 2D6 (CYP2D6) gene in patients with early onset of Parkinson's disease. Parkinsonism Relat Disord 13: 224-229, 2007.
15. Bianchi P, Kunduzova O, Masini E, Cambon C, Bani D, Raimondi L, Seguelas MH, Nistri S, Colucci W, Leducq N, and Parini A. Oxidative stress by monoamine oxidase mediates receptor-independent cardiomyocyte apoptosis by serotonin and postischemic myocardial injury. Circulation 112: 3297-3305, 2005.
16. Bokoch GM, Diebold B, Kim JS, and Gianni D. Emerging evidence for the importance of phosphorylation in the regulation of NADPH oxidases. Antioxid Redox Signal 11: 2429-2441, 2009.
17. Bortolato M, Chen K, and Shih JC. Monoamine oxidase inactivation: from pathophysiology to therapeutics. Adv Drug Deliv Rev 60: 1527-1533, 2008.
18. Bortolato M and Shih JC. Behavioral outcomes of monoamine oxidase deficiency: preclinical and clinical evidence. Int Rev Neurobiol 100: 13-42, 2011.
19. Bressler J, Pankow JS, Coresh J, and Boerwinkle E. Interaction between the NOS3 gene and obesity as a determinant of risk of type 2 diabetes: the atherosclerosis risk in communities study. PLoS One 8: e79466, 2013.
20. Brunner HG, Nelen M, Breakefield XO, Ropers HH, and van Oost BA. Abnormal behavior associated with a point mutation in the structural gene for monoamine oxidase A. Science 262: 578-580, 1993.
21. Brunner HG, Nelen MR, van Zandvoort P, Abeling NG, van Gennip AH, Wolters EC, Kuiper MA, Ropers HH, and van Oost BA. X-linked borderline mental retardation with prominent behavioral disturbance: phenotype, genetic localization, and evidence for disturbed monoamine metabolism. Am J Hum Genet 52: 1032-1039, 1993.
22. Butler R, Morris AD, Belch JJ, Hill A, and Struthers AD. Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension 35: 746-751, 2000.
23. Cappola TP, Kass DA, Nelson GS, Berger RD, Rosas GO, Kobeissi ZA, Marban E, and Hare JM.Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation 104: 2407-2411, 2001.
24. Carnesecchi S, Deffert C, Donati Y, Basset O, Hinz B, Preynat-Seauve O, Guichard C, Arbiser JL, Banfi B, Pache JC, Barazzone-Argiroffo C, and Krause KH. A key role for NOX4 in epithelial cell death during development of lung fibrosis. Antioxid Redox Signal 15: 607-619, 2011.
25. Closs EI, Ostad MA, Simon A, Warnholtz A, Jabs A, Habermeier A, Daiber A, Forstermann U, and Munzel T. Impairment of the extrusion transporter for asymmetric dimethyl-l-arginine: a novel mechanism underlying vasospastic angina. Biochem Biophys Res Commun 423: 208-223, 2012.
26. Collins FA, Murphy DL, Reiss AL, Sims KB, Lewis JG, Freund L, Karoum F, Zhu D, Maumenee IH, and Antonarakis SE. Clinical, biochemical, and neuropsychiatric evaluation of a patient with a contiguous gene syndrome due to a microdeletion Xp11.3 including the Norrie disease locus and monoamine oxidase (MAOA and MAOB) genes. Am J Med Genet 42: 127-134, 1992.
27. Costell MH, Ancellin N, Bernard RE, Zhao S, Upson JJ, Morgan LA, Maniscalco K, Olzinski AR, Ballard VL, Herry K, Grondin P, Dodic N, Mirguet O, Bouillot A, Gellibert F, Coatney RW, Lepore JJ, Jucker BM, Jolivette LJ, Willette RN, Schnackenberg CG, and Behm DJ. Comparison of soluble guanylate cyclase stimulators and activators in models of cardiovascular disease associated with oxidative stress. Front Pharmacol 3: 128, 2012.
28. Cross AR and Segal AW. The NADPH oxidase of professional phagocytes-prototype of the NOX electron transport chain systems. Biochim Biophys Acta 1657: 1-22, 2004.
29. Cucoranu I, Clempus R, Dikalova A, Phelan PJ, Ariyan S, Dikalov S, and Sorescu D. NAD(P)H oxidase 4 mediates transforming growth factor-beta1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circ Res 97: 900-907, 2005.
30. Derbyshire ER and Marletta MA. Structure and regulation of soluble guanylate cyclase. Annu Rev Biochem 81: 533-559, 2012.
31. Di Lisa F, Kaludercic N, Carpi A, Menabo R, and Giorgio M. Mitochondrial pathways for ROS formation and myocardial injury: the relevance of p66(Shc) and monoamine oxidase. Basic Res Cardiol 104: 131-139, 2009.
32. Dikalova A, Clempus R, Lassegue B, Cheng G, McCoy J, Dikalov S, San Martin A, Lyle A, Weber DS, Weiss D, Taylor WR, Schmidt HH, Owens GK, Lambeth JD, and Griendling KK. Nox1 overexpression potentiates angiotensin II-induced hypertension and vascular smooth muscle hypertrophy in transgenic mice. Circulation 112: 2668-2676, 2005.
33. Droge W. Free radicals in the physiological control of cell function. Physiol Rev 82: 47-95, 2002.
34. Edmondson DE, Mattevi A, Binda C, Li M, and Hubalek F. Structure and mechanism of monoamine oxidase. Curr Med Chem 11: 1983-1993, 2004.
35. Eiserich JP, Baldus S, Brennan ML, Ma W, Zhang C, Tousson A, Castro L, Lusis AJ, Nauseef WM, White CR, and Freeman BA. Myeloperoxidase, a leukocytederived vascular NO oxidase. Science 296: 2391-2394, 2002.
36. Elion GB. The purine path to chemotherapy. Science 244: 41-47, 1989.
37. Evgenov OV, Pacher P, Schmidt PM, Hasko G, Schmidt HH, and Stasch JP. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 5: 755-768, 2006.
38. Fang J and Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic followup study, 1971-1992. National Health and Nutrition Examination Survey. JAMA 283: 2404-2410, 2000.
39. Fini MA, Monks J, Farabaugh SM, and Wright RM. Contribution of xanthine oxidoreductase to mammary epithelial and breast cancer cell differentiation in part modulates inhibitor of differentiation-1. Mol Cancer Res 9: 1242-1254, 2011.
40. Frijhoff J WPG, Stocker R, Cheng D, Davies SS, Knight A, Taylor E, Ruskovska T, Gasparovic AC, Oettrich J, Zarkovic N, Weber D, Poulsen HE, Cuadrado A, Grune T, Schmidt HH, and Ghezzi P. Clinical relevance of biomarkers of oxidative stress. Antioxid Redox Signal 23: 1144-1170, 2015.
41. Fulton DJ. Nox5 and the regulation of cellular function. Antioxid Redox Signal 11: 2443-2452, 2009.
42. Furlong RA, Ho L, Rubinsztein JS, Walsh C, Paykel ES, and Rubinsztein DC. Analysis of the monoamine oxidase A (MAOA) gene in bipolar affective disorder by association studies, meta-analyses, and sequencing of the promoter. Am J Med Genet 88: 398-406, 1999.
43. Gaut JP, Byun J, Tran HD, Lauber WM, Carroll JA, Hotchkiss RS, Belaaouaj A, and Heinecke JW. Myeloperoxidase produces nitrating oxidants in vivo. J Clin Invest 109: 1311-1319, 2002.
44. Gavazzi G, Banfi B, Deffert C, Fiette L, Schappi M, Herrmann F, and Krause KH. Decreased blood pressure in NOX1-deficient mice. FEBS Lett 580: 497-504, 2006.
45. Gavazzi G, Deffert C, Trocme C, Schappi M, Herrmann FR, and Krause KH. NOX1 deficiency protects from aortic dissection in response to angiotensin II. Hypertension 50: 189-196, 2007.
46. Gheorghiade M, Greene SJ, Filippatos G, Erdmann E, Ferrari R, Levy PD, Maggioni A, Nowack C, and Mebazaa A. Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes. Eur J Heart Fail 14: 1056-1066, 2012.
47. Ghofrani HA, Galie N, Grimminger F, Grunig E, Humbert M, Jing ZC, Keogh AM, Langleben D, Kilama MO, Fritsch A, Neuser D, and Rubin LJ. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 369: 330-340, 2013.
48. Givertz MM, Anstrom KJ, Redfield MM, Deswal A, Haddad H, Butler J, Tang WH, DunlapME, LeWinter MM, Mann DL, Felker GM, O'Connor CM, Goldsmith SR, Ofili EO, Saltzberg MT, Margulies KB, Cappola TP, Konstam MA, Semigran MJ, McNulty SE, Lee KL, Shah MR, and Hernandez AF. Effects of xanthine oxidase inhibition in hyperuricemic heart failure patients: the xanthine oxidase inhibition for hyperuricemic heart failure patients (EXACT-HF) study. Circulation 131: 1763-1771, 2015.
49. Goettsch C, Babelova A, Trummer O, Erben RG, Rauner M, Rammelt S, Weissmann N, Weinberger V, Benkhoff S, Kampschulte M, Obermayer-Pietsch B, Hofbauer LC, Brandes RP, and Schroder K. NADPH oxidase 4 limits bone mass by promoting osteoclastogenesis. J Clin Invest 123: 4731-4738, 2013.
50. Gori T, Burstein JM, Ahmed S, Miner SE, Al-Hesayen A, Kelly S, and Parker JD. Folic acid prevents nitroglycerininduced nitric oxide synthase dysfunction and nitrate tolerance: a human in vivo study. Circulation 104: 1119-1123., 2001.
51. Gray SP, Di Marco E, Okabe J, Szyndralewiez C, Heitz F, Montezano AC, de Haan JB, Koulis C, El-Osta A, Andrews KL, Chin-Dusting JP, Touyz RM, Wingler K, Cooper ME, Schmidt HH, and Jandeleit-Dahm KA. NADPH oxidase 1 plays a key role in diabetes mellitus-accelerated atherosclerosis. Circulation 127: 1888-1902, 2013.
52. Guzik TJ, Chen W, Gongora MC, Guzik B, Lob HE, Mangalat D, Hoch N, Dikalov S, Rudzinski P, Kapelak B, Sadowski J, and Harrison DG. Calcium-dependent NOX5 nicotinamide adenine dinucleotide phosphate oxidase contributes to vascular oxidative stress in human coronary artery disease. J Am Coll Cardiol 52: 1803-1809, 2008.
53. Hampton MB, Kettle AJ, and Winterbourn CC. Inside the neutrophil phagosome: oxidants, myeloperoxidase, and bacterial killing. Blood 92: 3007-3017, 1998.
54. Hansel TT, Kharitonov SA, Donnelly LE, Erin EM, Currie MG, Moore WM, Manning PT, Recker DP, and Barnes PJ. A selective inhibitor of inducible nitric oxide synthase inhibits exhaled breath nitric oxide in healthy volunteers and asthmatics. FASEB J 17: 1298-1300, 2003.
55. Hecker L, Logsdon NJ, Kurundkar D, Kurundkar A, Bernard K, Hock T, Meldrum E, Sanders YY, and Thannickal VJ. Reversal of persistent fibrosis in aging by targeting Nox4-Nrf2 redox imbalance. Sci Transl Med 6: 231ra47, 2014.
56. Hecker L, Vittal R, Jones T, Jagirdar R, Luckhardt TR, Horowitz JC, Pennathur S, Martinez FJ, and Thannickal VJ. NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat Med 15: 1077-1081, 2009.
57. Heitzer T, Brockhoff C, Mayer B, Warnholtz A, Mollnau H, Henne S, Meinertz T, and Munzel T. Tetrahydrobiopterin improves endothelium-dependent vasodilation in chronic smokers: evidence for a dysfunctional nitric oxide synthase. Circ Res 86: E36-E41, 2000.
58. Heitzer T, Krohn K, Albers S, and Meinertz T. Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with Type II diabetes mellitus. Diabetologia 43: 1435-1438, 2000.
59. Heumuller S, Wind S, Barbosa-Sicard E, Schmidt HH, Busse R, Schroder K, and Brandes RP. Apocynin is not an inhibitor of vascular NADPH oxidases but an antioxidant. Hypertension 51: 211-217, 2008.
60. Hille R and Nishino T. Flavoprotein structure and mechanism. 4. Xanthine oxidase and xanthine dehydrogenase. FASEB J 9: 995-1003, 1995.
61. Hou YC, Janczuk A, and Wang PG. Current trends in the development of nitric oxide donors. Curr Pharm Des 5: 417-441, 1999.
62. Hultqvist M, Olsson LM, Gelderman KA, and Holmdahl R. The protective role of ROS in autoimmune disease. Trends Immunol 30: 201-208, 2009.
63. Jha JC, Gray SP, Barit D, Okabe J, El-Osta A, Namikoshi T, Thallas-Bonke V, Wingler K, Szyndralewiez C, Heitz F, Touyz RM, Cooper ME, Schmidt HH, and Jandeleit-Dahm KA. Genetic targeting or pharmacologic inhibition of NADPH oxidase nox4 provides renoprotection in long-term diabetic nephropathy. J Am Soc Nephrol 25: 1237-1254, 2014.
64. Johnson KR, Marden CC, Ward-Bailey P, Gagnon LH, Bronson RT, and Donahue LR. Congenital hypothyroidism, dwarfism, and hearing impairment caused by a missense mutation in the mouse dual oxidase 2 gene, Duox2. Mol Endocrinol 21: 1593-1602, 2007.
65. Kaludercic N, Carpi A, Nagayama T, Sivakumaran V, Zhu G, Lai EW, Bedja D, De Mario A, Chen K, Gabrielson KL, Lindsey ML, Pacak K, Takimoto E, Shih JC, Kass DA, Di Lisa F, and Paolocci N. Monoamine oxidase B prompts mitochondrial and cardiac dysfunction in pressure overloaded hearts. Antioxid Redox Signal 20: 267-280, 2014.
66. Kaludercic N, Deshwal S, and Di Lisa F. Reactive oxygen species and redox compartmentalization. Front Physiol 5: 285, 2014.
67. Kaludercic N, Mialet-Perez J, Paolocci N, Parini A, and Di Lisa F. Monoamine oxidases as sources of oxidants in the heart. J Mol Cell Cardiol 73: 34-42, 2014.
68. Kaludercic N, Takimoto E, Nagayama T, Feng N, Lai EW, Bedja D, Chen K, Gabrielson KL, Blakely RD, Shih JC, Pacak K, Kass DA, Di Lisa F, and Paolocci N. Monoamine oxidase A-mediated enhanced catabolism of norepinephrine contributes to adverse remodeling and pump failure in hearts with pressure overload. Circ Res 106: 193-202, 2010.
69. Kang SJ, Scott WK, Li YJ, Hauser MA, van der Walt JM, Fujiwara K, Mayhew GM, West SG, Vance JM, and Martin ER. Family-based case-control study of MAOA and MAOB polymorphisms in Parkinson disease. Mov Disord 21: 2175-2180, 2006.
70. Kareyeva AV, Grivennikova VG, Cecchini G, and Vinogradov AD. Molecular identification of the enzyme responsible for the mitochondrial NADH-supported ammonium-dependent hydrogen peroxide production. FEBS Lett 585: 385-389, 2011.
71. Kawahara T, Quinn MT, and Lambeth JD. Molecular evolution of the reactive oxygen-generating NADPH oxidase (Nox/Duox) family of enzymes. BMC Evol Biol 7: 109, 2007.
72. Kiss PJ, Knisz J, Zhang Y, Baltrusaitis J, Sigmund CD, Thalmann R, Smith RJ, Verpy E, and Banfi B. Inactivation of NADPH oxidase organizer 1 results in severe imbalance. Curr Biol 16: 208-213, 2006.
73. Klebanoff SJ. Myeloperoxidase-halide-hydrogen peroxide antibacterial system. J Bacteriol 95: 2131-2138, 1968.
74. Klebanoff SJ. Oxygen metabolism and the toxic properties of phagocytes. Ann Intern Med 93: 480-489, 1980.
75. Kleikers PW, Wingler K, Hermans JJ, Diebold I, Altenhofer S, Radermacher KA, Janssen B, Gorlach A, and Schmidt HH. NADPH oxidases as a source of oxidative stress and molecular target in ischemia/reperfusion injury. J Mol Med (Berl) 90: 1391-1406, 2012.
76. Kleinschnitz C, Grund H, Wingler K, Armitage ME, Jones E, Mittal M, Barit D, Schwarz T, Geis C, Kraft P, Barthel K, Schuhmann MK, Herrmann AM, Meuth SG, Stoll G, Meurer S, Schrewe A, Becker L, Gailus-Durner V, Fuchs H, Klopstock T, de Angelis MH, Jandeleit-Dahm K, Shah AM, Weissmann N, and Schmidt HH. Post-stroke inhibition of induced NADPH oxidase type 4 prevents oxidative stress and neurodegeneration. PLoS Biol 8: pii: e1000479, 2010.
77. Knapp LT and Klann E. Superoxide-induced stimulation of protein kinase C via thiol modification and modulation of zinc content. J Biol Chem 275: 24136-24145, 2000.
78. Korichneva I, Hoyos B, Chua R, Levi E, and Hammerling U. Zinc release from protein kinase C as the common event during activation by lipid second messenger or reactive oxygen. J Biol Chem 277: 44327-44331, 2002.
79. Krause KH, Lambeth D, and Kronke M. NOX enzymes as drug targets. Cell Mol Life Sci 69: 2279-2282, 2012.
80. Kreatsoulas C and Anand SS. The impact of social determinants on cardiovascular disease. Can J Cardiol 26 Suppl, 8c-13c, 2010.
81. Lapchak PA. A critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy Expert Opin Pharmacother 11: 1753-1763, 2010.
82. Lau D, Mollnau H, Eiserich JP, Freeman BA, Daiber A, Gehling UM, Brummer J, Rudolph V, Munzel T, Heitzer T, Meinertz T, and Baldus S. Myeloperoxidase mediates neutrophil activation by association with CD11b/CD18 integrins. Proc Natl Acad Sci USA 102: 431-436, 2005.
83. Laursen JB, Somers M, Kurz S, McCann L, Warnholtz A, Freeman BA, Tarpey M, Fukai T, and Harrison DG. Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation 103: 1282-1288, 2001.
84. Leto TL, Morand S, Hurt D, and Ueyama T. Targeting and regulation of reactive oxygen species generation by Nox family NADPH oxidases. Antioxid Redox Signal 11: 2607-2619, 2009.
85. Li J, Wang Y, Hu S, Zhou R, Yu X, Wang B, Guan L, Yang L, Zhang F, and Faraone SV. The monoamine oxidase B gene exhibits significant association to ADHD. Am J Med Genet B Neuropsychiatr Genet 147: 370-374, 2008.
86. Lim LC, Powell J, Sham P, Castle D, Hunt N, Murray R, and Gill M. Evidence for a genetic association between alleles of monoamine oxidase A gene and bipolar affective disorder. Am J Med Genet 60: 325-331, 1995.
87. Liu VW and Huang PL. Cardiovascular roles of nitric oxide: a review of insights from nitric oxide synthase gene disrupted mice. Cardiovasc Res 77: 19-29, 2008.
88. Mann J and Chiu E. Platelet monoamine oxidase activity in Huntington's chorea. J Neurol Neurosurg Psychiatry 41: 809-812, 1978.
89. Martyn KD, Frederick LM, von Loehneysen K, Dinauer MC, and Knaus UG. Functional analysis of Nox4 reveals unique characteristics compared to other NADPH oxidases. Cell Signal 18: 69-82, 2006.
90. Matsuno K, Yamada H, Iwata K, Jin D, Katsuyama M, Matsuki M, Takai S, Yamanishi K, Miyazaki M, Matsubara H, and Yabe-Nishimura C. Nox1 is involved in angiotensin II-mediated hypertension: a study in Nox1-deficient mice. Circulation 112: 2677-2685, 2005.
91. Maurel A, Hernandez C, Kunduzova O, Bompart G, Cambon C, Parini A, and Frances B. Age-dependent increase in hydrogen peroxide production by cardiac monoamine oxidase A in rats. Am J Physiol Heart Circ Physiol 284: H1460-H1467, 2003.
92. McCord JM. Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med 312: 159-163, 1985.
93. Melichar VO, Behr-Roussel D, Zabel U, Uttenthal LO, Rodrigo J, Rupin A, Verbeuren TJ, Kumar HSA, and Schmidt HH. Reduced cGMP signaling associated with neointimal proliferation and vascular dysfunction in latestage atherosclerosis. Proc Natl Acad Sci USA 101: 16671-16676, 2004.
94. Menazza S, Blaauw B, Tiepolo T, Toniolo L, Braghetta P, Spolaore B, Reggiani C, Di Lisa F, Bonaldo P, and Canton M. Oxidative stress by monoamine oxidases is causally involved in myofiber damage in muscular dystrophy. Hum Mol Genet 19: 4207-4215, 2010.
95. Meurer S, Pioch S, Pabst T, Opitz N, SchmidtPM, Beckhaus T, Wagner K, Matt S, Gegenbauer K, Geschka S, Karas M, Stasch JP, Schmidt HH, and Muller-Esterl W. Nitric oxideindependent vasodilator rescues heme-oxidized soluble guanylate cyclase from proteasomal degradation. Circ Res 105: 33-41, 2009.
96. Miller RT, Martasek P, Roman LJ, Nishimura JS, and Masters BS. Involvement of the reductase domain of neuronal nitric oxide synthase in superoxide anion production. Biochemistry 36: 15277-15284, 1997.
97. Mittal M, Roth M, Konig P, Hofmann S, Dony E, Goyal P, Selbitz AC, Schermuly RT, Ghofrani HA, Kwapiszewska G, Kummer W, Klepetko W, Hoda MA, Fink L, Hanze J, Seeger W, Grimminger F, Schmidt HH, and Weissmann N. Hypoxia-dependent regulation of nonphagocytic NADPH oxidase subunit NOX4 in the pulmonary vasculature. Circ Res 101: 258-267, 2007.
98. Montezano AC and Touyz RM. Reactive oxygen species and endothelial function-role of nitric oxide synthase uncoupling and Nox family nicotinamide adenine dinucleotide phosphate oxidases. Basic Clin Pharmacol Toxicol 110: 87-94, 2012.
99. Murakami N, Ohtsubo T, Kansui Y, Goto K, Noguchi H, Haga Y, Nakabeppu Y, Matsumura K, and Kitazono T. Mice heterozygous for the xanthine oxidoreductase gene facilitate lipid accumulation in adipocytes. Arterioscler Thromb Vasc Biol 34: 44-51, 2014.
100. Murphy DL, Sims KB, Karoum F, de la Chapelle A, Norio R, Sankila EM, and Breakefield XO. Marked amine and amine metabolite changes in Norrie disease patients with an X-chromosomal deletion affecting monoamine oxidase. J Neurochem 54: 242-247, 1990.
101. Nishino T. The conversion from the dehydrogenase type to the oxidase type of rat liver xanthine dehydrogenase by modification of cysteine residues with fluorodinitrobenzene. J Biol Chem 272: 29859-29864, 1997.
102. Nisimoto Y, Diebold BA, Constentino-Gomes D, and Lambeth JD. Nox4: a hydrogen peroxide-generating oxygen sensor. Biochemistry 53: 5111-5120, 2014.
103. Nlandu Khodo S, Dizin E, Sossauer G, Szanto I, Martin PY, Feraille E, Krause KH, and de Seigneux S. NADPHoxidase 4 protects against kidney fibrosis during chronic renal injury. J Am Soc Nephrol 23: 1967-1976, 2012.
104. Odobasic D, Kitching AR, Yang Y, O'Sullivan KM, Muljadi RC, Edgtton KL, Tan DS, Summers SA, Morand EF, and Holdsworth SR. Neutrophil myeloperoxidase regulates T-cell-driven tissue inflammation in mice by inhibiting dendritic cell function. Blood 121: 4195-4204, 2013.
105. Pullen SS, Lincoln KA, Harrison PC, Chen H, Wang H, Clifford H, Qian H, Wong D, Sarko C, Brenneman J, Fryer R, Richman J, Reinhart GA, and Boustany C. A soluble guanylate cyclase activator protects from diabetic nephropathy beyond standard of care in the ZSF1 rat. BMC Pharmacology and Toxicology 2015 16(Suppl): A4
106. Paffenholz R, Bergstrom RA, Pasutto F, Wabnitz P, Munroe RJ, Jagla W, Heinzmann U, Marquardt A, Bareiss A, Laufs J, Russ A, Stumm G, Schimenti JC, and Bergstrom DE. Vestibular defects in head-tilt mice result from mutations in Nox3, encoding an NADPH oxidase. Genes Dev 18: 486-491, 2004.
107. Peskin AV, Midwinter RG, Harwood DT, and Winterbourn CC. Chlorine transfer between glycine, taurine, and histamine: reaction rates and impact on cellular reactivity. Free Radic Biol Med 37: 1622-1630, 2004.
108. Pieske B, Butler J, Filippatos G, Lam C, Maggioni AP, Ponikowski P, Shah S, Solomon S, Kraigher-Krainer E, Samano ET, Scalise AV, Muller K, Roessig L, and Gheorghiade M. Rationale and design of the SOluble guanylate cyclase stimulatoR in heArT failurE Studies (SOCRATES). Eur J Heart Fail 16: 1026-1038, 2014.
109. Piret SE, Esapa CT, Gorvin CM, Head R, Loh NY, Devuyst O, Thomas G, Brown SD, Brown M, Croucher P, Cox R, and Thakker RV. A mouse model of early-onset renal failure due to a xanthine dehydrogenase nonsense mutation. PLoS One 7: e45217, 2012.
110. Podrez EA, Abu-Soud HM, and Hazen SL. Myeloperoxidase-generated oxidants and atherosclerosis. Free Radic Biol Med 28: 1717-1725, 2000.
111. Prakash A, Bharti K, and Majeed AB. Zinc: indications in brain disorders. Fundam Clin Pharmacol 29: 131-149, 2015.
112. Radermacher KA, Wingler K, Kleikers P, Altenhofer S, Jr., Hermans J, Kleinschnitz C, and Hhw Schmidt H. The 1027th target candidate in stroke: will NADPH oxidase hold up Exp Transl Stroke Med 4: 11, 2012.
113. Radermacher KA, Wingler K, Langhauser F, Altenhofer S, Kleikers P, Hermans JJ, Hrabe de Angelis M, Kleinschnitz C, and Schmidt HH. Neuroprotection after stroke by targeting NOX4 as a source of oxidative stress. Antioxid Redox Signal 18: 1418-1427, 2013.
114. Ramsay RR. Monoamine oxidases: the biochemistry of the proteins as targets in medicinal chemistry and drug discovery. Curr Top Med Chem 12: 2189-2209, 2012.
115. Ribases M, Ramos-Quiroga JA, Hervas A, Bosch R, Bielsa A, Gastaminza X, Artigas J, Rodriguez-Ben S, Estivill X, Casas M, Cormand B, and Bayes M. Exploration of 19 serotoninergic candidate genes in adults and children with attention-deficit/hyperactivity disorder identifies association for 5HT2A, DDC and MAOB. Mol Psychiatry 14: 71-85, 2009.
116. Rodriguez-Munoz M, de la Torre-Madrid E, Sanchez-Blazquez P, and Garzon J. NO-released zinc supports the simultaneous binding of Raf-1 and PKCgamma cysteinerich domains to HINT1 protein at the mu-opioid receptor. Antioxid Redox Signal 14: 2413-2425, 2011.
117. Rubinsztein DC, Leggo J, Goodburn S, Walsh C, Jain S, and Paykel ES. Genetic association between monoamine oxidase A microsatellite and RFLP alleles and bipolar affective disorder: analysis and meta-analysis. Hum Mol Genet 5: 779-782, 1996.
118. Rudolph TK, Rudolph V, Witte A, Klinke A, Szoecs K, Lau D, Heitzer T, Meinertz T, and Baldus S. Liberation of vessel adherent myeloperoxidase by enoxaparin improves endothelial function. Int J Cardiol 140: 42-47, 2008.
119. Sanchez-Blazquez P, Rodriguez-Munoz M, Bailon C, and Garzon J. GPCRs promote the release of zinc ions mediated by nNOS/NO and the redox transducer RGSZ2 protein. Antioxid Redox Signal 17: 1163-1177, 2012.
120. Sandler M, Glover V, Clow A, and Jarman J. Monoamine oxidase-B, monoamine oxidase-B inhibitors, and Parkinson's disease. A role for superoxide dismutase Adv Neurol 60: 238-241, 1993.
121. Saura J, Andres N, Andrade C, Ojuel J, Eriksson K, and Mahy N. Biphasic and region-specific MAO-B response to aging in normal human brain. Neurobiol Aging 18: 497-507, 1997.
122. Savenkova ML, Mueller DM, and Heinecke JW. Tyrosyl radical generated by myeloperoxidase is a physiological catalyst for the initiation of lipid peroxidation in low density lipoprotein. J Biol Chem 269: 20394-20400, 1994.
123. Schappi MG, Jaquet V, Belli DC, and Krause KH. Hyperinflammation in chronic granulomatous disease and anti-inflammatory role of the phagocyte NADPH oxidase. Semin Immunopathol 30: 255-271, 2008.
124. Schieber M and Chandel NS. ROS function in redox signaling and oxidative stress. Curr Biol 24: R453-R462, 2014.
125. Schmidt HH, Stocker R, Vollbracht C, Paulsen G, Riley DP, Daiber A, and Cuadrado A. Antioxidants in Translational Medicine. Antioxid Redox Signal 23: 1130-1143, 2015.
126. Schmidt HH and Walter U. NO at work. Cell 78: 919-925, 1994.
127. Schroder K, Vecchione C, Jung O, Schreiber JG, Shiri-Sverdlov R, van Gorp PJ, Busse R, and Brandes RP. Xanthine oxidase inhibitor tungsten prevents the development of atherosclerosis in ApoE knockout mice fed a Western-type diet. Free Radic Biol Med 41: 1353-1360, 2006.
128. Schuhmacher S, Wenzel P, Schulz E, Oelze M, Mang C, Kamuf J, Gori T, Jansen T, Knorr M, Karbach S, Hortmann M, Mathner F, Bhatnagar A, Forstermann U, Li H, Munzel T, and Daiber A. Pentaerythritol tetranitrate improves angiotensin II-induced vascular dysfunction via induction of heme oxygenase-1. Hypertension 55: 897-904, 2010.
129. Schulz E, Wenzel P, Munzel T, and Daiber A. Mitochondrial redox signaling: interaction of mitochondrial reactive oxygen species with other sources of oxidative stress. Antioxid Redox Signal 20: 308-324, 2014.
130. Serrander L, Cartier L, Bedard K, Banfi B, Lardy B, Plastre O, Sienkiewicz A, Forro L, Schlegel W, and Krause KH. NOX4 activity is determined by mRNA levels and reveals a unique pattern of ROS generation. Biochem J 406: 105-114, 2007.
131. Sims KB, de la Chapelle A, Norio R, Sankila EM, Hsu YP, Rinehart WB, Corey TJ, Ozelius L, Powell JF, Bruns G, et al. Monoamine oxidase deficiency in males with an X chromosome deletion. Neuron 2: 1069-1076, 1989.
132. Singh C, Bortolato M, Bali N, Godar SC, Scott AL, Chen K, Thompson RF, and Shih JC. Cognitive abnormalities and hippocampal alterations in monoamine oxidase A and B knockout mice. Proc Natl Acad Sci USA 110: 12816-12821, 2013.
133. Stasch JP, Dembowsky K, Perzborn E, Stahl E, and Schramm M. Cardiovascular actions of a novel NOindependent guanylyl cyclase stimulator, BAY 41-8543: in vivo studies. Br J Pharmacol 135: 344-355, 2002.
134. Stasch JP, Schlossmann J, and Hocher B. Renal effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence. Curr Opin Pharmacol 21c: 95-104, 2015.
135. Stasch JP, Schmidt PM, Nedvetsky PI, Nedvetskaya TY, H S AK, Meurer S, Deile M, Taye A, Knorr A, Lapp H, Muller H, Turgay Y, Rothkegel C, Tersteegen A, Kemp-Harper B, Muller-Esterl W, and Schmidt HH. Targeting the hemeoxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J Clin Invest 116: 2552-2561, 2006.
136. Steinhubl SR. Why have antioxidants failed in clinical trials Am J Cardiol 101: 14d-19d, 2008.
137. Stover JF, Belli A, Boret H, Bulters D, Sahuquillo J, Schmutzhard E, Zavala E, Ungerstedt U, Schinzel R, and Tegtmeier F. Nitric oxide synthase inhibition with the antipterin VAS203 improves outcome in moderate and severe traumatic brain injury: a placebo-controlled randomized Phase IIa trial (NOSTRA). J Neurotrauma 31: 1599-1606, 2014.
138. Sturza A, Leisegang MS, Babelova A, Schroder K, Benkhoff S, Loot AE, Fleming I, Schulz R, Muntean DM, and Brandes RP. Monoamine oxidases are mediators of endothelial dysfunction in the mouse aorta. Hypertension 62: 140-146, 2013.
139. Suzuki H, DeLano FA, Parks DA, Jamshidi N, Granger DN, Ishii H, Suematsu M, Zweifach BW, and Schmid-Schonbein GW. Xanthine oxidase activity associated with arterial blood pressure in spontaneously hypertensive rats. Proc Natl Acad Sci USA 95: 4754-4759, 1998.
140. Sydow K and Munzel T. ADMA and oxidative stress. Atheroscler Suppl 4: 41-51, 2003.
141. Thanan R, Oikawa S, Hiraku Y, Ohnishi S, Ma N, Pinlaor S, Yongvanit P, Kawanishi S, and Murata M. Oxidative stress and its significant roles in neurodegenerative diseases and cancer. Int J Mol Sci 16: 193-217, 2014.
142. Tsutsui M, Shimokawa H, Morishita T, Nakashima Y, and Yanagihara N. Development of genetically engineered mice lacking all three nitric oxide synthases. J Pharmacol Sci 102: 147-154, 2006.
143. Van der Schueren BJ, Lunnon MW, Laurijssens BE, Guillard F, Palmer J, Van Hecken A, Depre M, Vanmolkot FH, and de Hoon JN. Does the unfavorable pharmacokinetic and pharmacodynamic profile of the iNOS inhibitor GW273629 lead to inefficacy in acute migraine J Clin Pharmacol 49: 281-290, 2009.
144. Villeneuve C, Guilbeau-Frugier C, Sicard P, Lairez O, Ordener C, Duparc T, De Paulis D, Couderc B, Spreux-Varoquaux O, Tortosa F, Garnier A, Knauf C, Valet P, Borchi E, Nediani C, Gharib A, Ovize M, Delisle MB, Parini A, and Mialet-Perez J. p53-PGC-1alpha pathway mediates oxidative mitochondrial damage and cardiomyocyte necrosis induced by monoamine oxidase-A upregulation: role in chronic left ventricular dysfunction in mice. Antioxid Redox Signal 18: 5-18, 2013.
145. von Leitner EC, Klinke A, Atzler D, Slocum JL, Lund N, Kielstein JT, Maas R, Schmidt-Haupt R, Pekarova M, Hellwinkel O, Tsikas D, D'Alecy LG, Lau D, Willems S, Kubala L, Ehmke H, Meinertz T, Blankenberg S, Schwedhelm E, Gadegbeku CA, Boger RH, Baldus S, and Sydow K. Pathogenic cycle between the endogenous nitric oxide synthase inhibitor asymmetrical dimethylarginine and the leukocyte-derived hemoprotein myeloperoxidase. Circulation 124: 2735-2745, 2011.
146. Wang-Rosenke Y, Mika A, Khadzhynov D, Loof T, Neumayer HH, and Peters H. Stimulation of soluble guanylate cyclase improves renal recovery after relief of unilateral ureteral obstruction. J Urol 186: 1142-1149, 2011.
147. Wang-Rosenke Y, Mika A, Khadzhynov D, Loof T, Neumayer HH, and Peters H. Impact of biological gender and soluble guanylate cyclase stimulation on renal recovery after relief of unilateral ureteral obstruction. J Urol 188: 316-323, 2012.
148. Weisskopf MG, O'Reilly E, Chen H, Schwarzschild MA, and Ascherio A. Plasma urate and risk of Parkinson's disease. Am J Epidemiol 166: 561-567, 2007.
149. Weitzdoerfer R, Hoeger H, Engidawork E, Engelmann M, Singewald N, Lubec G, and Lubec B. Neuronal nitric oxide synthase knock-out mice show impaired cognitive performance. Nitric Oxide 10: 130-140, 2004.
150. Whibley A, Urquhart J, Dore J, Willatt L, Parkin G, Gaunt L, Black G, Donnai D, and Raymond FL. Deletion of MAOA and MAOB in a male patient causes severe developmental delay, intermittent hypotonia and stereotypical hand movements. Eur J Hum Genet 18: 1095-1099, 2010.
151. Wilkinson-Berka JL, Deliyanti D, Rana I,Miller AG, Agrotis A, Armani R, Szyndralewiez C, Wingler K, Touyz RM, Cooper ME, Jandeleit-Dahm KA, and Schmidt HH. NADPH oxidase, NOX1, mediates vascular injury in ischemic retinopathy. Antioxid Redox Signal 20: 2726-2740, 2014.
152. Wind S, Beuerlein K, Armitage ME, Taye A, Kumar AH, Janowitz D, Neff C, Shah AM, Wingler K, and Schmidt HH. Oxidative stress and endothelial dysfunction in aortas of aged spontaneously hypertensive rats by NOX1/2 is reversed by NADPH oxidase inhibition. Hypertension 56: 490-497, 2010.
153. Wind S, Beuerlein K, Eucker T, Muller H, Scheurer P, Armitage ME, Ho H, Schmidt HH, and Wingler K. Comparative pharmacology of chemically distinct NADPH oxidase inhibitors. Br J Pharmacol 161: 885-898, 2010.
154. Winterbourn CC and Kettle AJ. Biomarkers of myeloperoxidase-derived hypochlorous acid. Free Radic Biol Med 29: 403-409, 2000.
155. Wu JB, Shao C, LiX, Li Q, Hu P, Shi C, Li Y, Chen YT, Yin F, Liao CP, Stiles BL, Zhau HE, Shih JC, and Chung LW. Monoamine oxidase A mediates prostate tumorigenesis and cancer metastasis. J Clin Invest 124: 2891-2908, 2014.
156. Xia Y and Zweier JL. Direct measurement of nitric oxide generation from nitric oxide synthase. Proc Natl Acad Sci USA 94: 12705-12710, 1997.
157. Youdim MB, Edmondson D, and Tipton KF. The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 7: 295-309, 2006.